CD4 and lymphoma: While additional investigation to determine the mechanisms behind the reduced or absent expression of CD4 + T cells inside the lymphoma follicles is warranted, the prognostic power of the BioFLIPI will be useful in the design of clinical trials as it identifies patients at the highest risk of early failure who may benefit most from more intensive therapies or novel frontline regimens.